Blood-based Alzheimer’s disease (AD) biomarker testing could be used as a simple, accessible, and scalable approach to help support the diagnosis of AD, avoiding the complexity of cerebrospinal fluid (CSF) sampling, and the high costs and poor availability of PET biomarker testing.
Different research studies have shown that plasma phosphorylated Tau forms are good candidates to become an AD biomarker1,2. In particular, pTau 181 has shown good concordance with amyloid PET, has proven to differentiate between AD and non-AD neurodegenerative diseases, is able to predict progression to AD3-6, and could potentially be useful for drug monitoring. This topic was discussed in detail during the second webinar of the Fujirebio Neuro webinar series with guest speaker Prof. Dr. Oskar Hansson.
Making such blood-based biomarkers available on fully automated immuno-analyzers used in clinical routine would allow analysis in general clinical lab settings. The LUMIPULSE® G platform is such a robust platform, already in use worldwide for determining CSF biomarker concentrations, and capable of measuring low concentrations precisely as needed for blood-based AD biomarker assessments.
A status update of the Lumipulse G pTau 181 Plasma development was given by our colleague Manu Vandijck during the webinar mentioned above and the analytical performance of the prototype assay was summarized in poster format for your convenience.
Feel free to contact us for more information.
1. Zetterberg H. & Blennow K., 2021, Mol Neurodegener, 16: 10
2. Largent E. et al., 2021, JAMA Neurol, 78 (4): 379 – 380
3. Palmqvist S. et al., 2019, EMBO Mol Med, 11 (12): e11170
4. Janelidze S. et al., 2020, Nat Med., 26: 379 – 386
5. Mielke M. et al., 2018, Alzheimers Dement, 14 (8): 989 – 997
6. Karikari T. et al., 2020, Lancet Neurol, 19 (5): 422-433